Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 127,632 |
Ending reported balance
After 2026-06-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-17 · Grant · Acquired 88,424 · Balance 131,595 F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Row 2 · 2026-06-18 · Sale · Disposed 3,963 · Balance 127,632 F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
F2: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 3,963 | $3.18 | $12,602.34 |
DisclosureSEC source: 0001601830-26-000082 · wk-form4_1782160319.xml · nonDerivative · entry 2 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,632 F2 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:32 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 88,424 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000082 · wk-form4_1782160319.xml · nonDerivative · entry 1 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,595 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 21:04 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 4,386 | $3.54 | $15,526.44 |
DisclosureSEC source: 0002060594-26-000003 · wk-form4_1780607095.xml · nonDerivative · entry 1 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,171 F1 · kind: This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2026. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 22,016 | $0.00 Strike: $5.11 | $0.00 |
DisclosureSEC source: 0001601830-25-000108 · wk-form4_1750713775.xml · derivative · entry 2 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,016 Underlying: Class A Common Stock · 22,016 shares Expires 2035-06-18 F2 · derivative.exercise_date: The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 21:23 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 11,008 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000108 · wk-form4_1750713775.xml · nonDerivative · entry 1 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,557 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 73,099 | $0.00 Strike: $6.84 | $0.00 |
DisclosureSEC source: 0001601830-25-000048 · wk-form4_1742416041.xml · derivative · entry 2 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,099 Underlying: Class A Common Stock · 73,099 shares Expires 2035-03-17 F2 · derivative.exercise_date: Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:27 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 36,549 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-25-000048 · wk-form4_1742416041.xml · nonDerivative · entry 1 Bumpus Namandje · CIK 0002060594 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,549 F1 · kind: Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of March 17, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.